GLOBOVAX - Trademark Details
Status: 602 - Abandoned-Failure To Respond Or Late Response
Serial Number
86879881
Word Mark
GLOBOVAX
Status
602 - Abandoned-Failure To Respond Or Late Response
Status Date
2018-06-12
Filing Date
2016-01-19
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2016-09-06
Attorney Name
Law Office Assigned Location Code
L80
Employee Name
HACK, ANDREA R
Statements
Goods and Services
adjuvants for medical purposes; amino acids for medical purposes; amino acids for veterinary purposes; soap-bark tree, quillaja, quillais and Quillaja saponaria Molina barks for pharmaceutical purposes; biological preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; biological preparations for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; chemical reagents for medical or veterinary purposes; chemical preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemical preparations for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemical preparations for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemico-pharmaceutical preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; drugs for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; glucose for medical purposes; milk sugar for pharmaceutical purposes; lactose for pharmaceutical purposes; medicinal roots; medicinal herbs; medicinal oils; medicinal infusions for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicines for human purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicines for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; pharmaceutical preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; phosphates for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; potassium salts for medical purposes; reagent paper for medical or veterinary purposes; mineral salts for medical purposes; sodium salts for medical purposes; sugar for medical purposes; vaccines; veterinary preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; yeast for pharmaceutical purposes; acetates for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; acids for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; alginates for pharmaceutical purposes; blood for medical purposes; blood plasma; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; diastase for medical purposes; enzyme preparations for medical purposes; enzymes for medical purposes; ferments for pharmaceutical purposes; medicated pastilles for pharmaceutical purposes; medicated lozenges for pharmaceutical purposes; flour for pharmaceutical purposes; meal for pharmaceutical purposes; hormones for medical purposes; milk ferments for pharmaceutical purposes; cultures of microorganisms for medical and veterinary use; preparations of microorganisms for medical and veterinary use, namely, nutritive substances for microorganisms for medical and veterinary use; serotherapeutic medicines for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicated serums for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; stem cells for medical purposes; anti-cancer preparations; adjuvants for use with vaccines; biological preparations for the treatment of cancer. drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; ferments for medical or veterinary use; human vaccine preparations; medicinal preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; reagents for medical use; vaccine adjuvants; vaccine preparations; vaccine stabilizers
Pseudo Mark
GLOBALL VAX
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2016-01-25
Primary Code
005
Correspondences
Name
JONATHAN O. OWENS
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2016-01-22 | NEW APPLICATION ENTERED IN TRAM |
2016-01-25 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2016-01-26 | NOTICE OF PSEUDO MARK E-MAILED |
2016-02-08 | ASSIGNED TO EXAMINER |
2016-02-08 | NON-FINAL ACTION WRITTEN |
2016-02-08 | NON-FINAL ACTION E-MAILED |
2016-02-08 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2016-07-14 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2016-07-14 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2016-07-15 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2016-07-21 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2016-08-02 | ASSIGNED TO LIE |
2016-08-03 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
2016-08-17 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2016-09-06 | PUBLISHED FOR OPPOSITION |
2016-09-06 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2016-11-01 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2017-03-10 | TEAS EXTENSION RECEIVED |
2017-03-10 | EXTENSION 1 FILED |
2017-03-10 | EXTENSION 1 GRANTED |
2017-03-14 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2017-10-09 | TEAS PETITION TO AMEND BASIS RECEIVED |
2017-10-27 | TEAS EXTENSION RECEIVED |
2017-10-27 | EXTENSION 2 FILED |
2017-10-27 | EXTENSION 2 GRANTED |
2017-10-31 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2017-10-31 | ASSIGNED TO PETITION STAFF |
2017-11-02 | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED |
2017-11-02 | ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED |
2017-11-14 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
2017-10-27 | NOTICE OF ALLOWANCE CANCELLED |
2017-11-14 | CASE RETURNED TO EXAMINATION |
2017-11-14 | NON-FINAL ACTION WRITTEN |
2017-11-14 | NON-FINAL ACTION E-MAILED |
2017-11-14 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2018-02-20 | ASSIGNED TO EXAMINER |
2018-06-12 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
2018-06-12 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND |